Press Announcements > FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

Press Announcements > FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia

08/01/2017 11:10 AM EDT

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.